Background: antihypertensive medications have long been implicated as a potential cause of falls in older people but, despite their widespread prescribing, the size of class-specific adverse effects remains unclear. Aim: to determine the role of antihypertensive medications in older people with a recorded fall in primary care. Design: case-control study. Setting: UK general practices contributing data to The Health Improvement Network primary care database. Methods: patients over 60 years of age with a first fall recorded between 2003 and 2006 were selected, and up to six controls per case matched by age, gender and general practice. We used conditional logistic regression to estimate odds ratios for ever exposure, and current/previous exposure to the main classes of antihypertensives, adjusting for co-morbidity. We also examined the effect of the time interval from first prescription to first fall. Results: amongst our 9,682 cases, we found an increased risk of current prescribing of thiazides (odds ratio (OR) 1.25; 95% confidence interval 1.15-1.36). At 3 weeks after first prescribing the risk remained 4.28 (1.19-15.42). We found a reduced risk for current prescribing of beta blockers (OR 0.90;). There was no significant association with current prescribing of any other class of antihypertensive. Conclusions: the study provides evidence that current prescribing of thiazides is associated with an increased risk of falling and that this is strongest in the 3 weeks following the first prescription.
Introduction
Antihypertensive medications have long been implicated as a potential cause of falls in older people, via orthostatic hypotension [1] . A meta-analysis of small studies found no overall association with falls for the main classes of antihypertensives. The review highlighted uncertainty about the extent to which the presence of a real effect may be obscured by the variable role of confounding by indication between pooled studies [2] . Nevertheless, despite their widespread prescribing, there remains little recent data for classspecific effects on falls. Therefore, we have performed a case-control study using prospectively collected data from primary care physicians in the United Kingdom to determine the role of antihypertensive medications in older people with a recorded fall in primary care.
Methods
The Health Improvement Network (THIN) is a longitudinal primary care database with a patient demographic profile similar to the general population in the United Kingdom. It contains diagnostic and prescribing data recorded by primary care physicians as part of routine clinical care. It includes information from secondary hospital referrals and emergency admissions and information about date and cause of death. We analysed data from the October 2008 release of THIN but have included in the study population only the 386 primary care practices who contributed data for the entire period [2003] [2004] [2005] [2006] and only those patients aged 60 years or over during the study period.
Cases were defined as people in the study population who experienced their first recorded fall during the study period and who had been contributing data for at least 1 year prior to the fall. We defined a first fall as the first event recorded using Read codes (diagnostic terms) with descriptions relating to falls. A list of the codes is available on request.
For each case, we randomly selected up to six general population controls who had no recorded falls, matching on age, sex and primary care practice. Each control had to be contributing data at the date of and for the year running up to the index event.
Our main exposures of interest were prescriptions for the main classes of medication recommended by the National Institute for Health and Clinical Excellence (NICE) guidelines for the treatment of hypertension [3] : thiazide-type diuretics, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists and beta blockers. We extracted data on prescriptions for antihypertensive medications which were issued prior to index date, grouping them according to their classification in the British National Formulary [4] .
Firstly, we classified exposure to each class of drugs in terms of the elapsed time between the index event and final preceding prescription, as follows: ever prescribed, current (last prescription within 60 days of index event), recent (60-120 days), previous (more than 120 days) or never prescribed. Our main potential confounders were pre-existing diagnosis of coronary heart disease (CHD), heart failure, atrial fibrillation, diabetes, other co-morbidity or prescribing of other antihypertensivesor antipsychotics. Our measure of general co-morbidity was the Charlson index which is a marker of 1-year mortality based on previous diagnoses of 17 diseases, including myocardial infarction, congestive heart failure, peripheral vascular disease, diabetes and cerebrovascular disease [5] .
Secondly, we explored the extent to which an increased risk of falling might be associated with the initiation of prescribing. We did this by categorising first falls in terms of the number of weeks of elapsed time from the time of the first prescription. We subdivided the first week into 0 days and 1-7 days in order to separate out the effect of any ascertainment bias at the time of prescribing.
Using the same methods, we examined the effect of prescriptions for antidepressants, to validate our data by testing whether it exhibits the positive association for which there is already consistent evidence in the literature [6, 7] .
Analysis
We used conditional logistic regression to estimate odds ratios for each exposure, matching by age, gender and practice. Initially, we estimated odds ratios for each of our exposures and confounders in a series of univariate models, comparing people who had ever/never been prescribed each class of antihypertensives. Amongst those people ever prescribed, we also calculated odds ratios for each class of antihypertensives for people currently/recently/previously prescribed.
For each class of antihypertensive, we explored the influence of confounders via bivariate models, in which we looked for a change in the odds ratio for exposure of 10% or more with the addition to the model of the putative confounder. We developed multivariate models to mutually adjust for prescriptions of other classes of antihypertensive medications. We tested for interaction with age using the likelihood ratio test.
We used a similar approach to explore the relationship of first fall to first prescription.
Our power calculation showed that a study of 9,600 cases with six controls would provide 95% power to detect a risk ratio of 1.2 or greater, using a 5% significance level, assuming an exposure rate of 5% amongst controls.
We used STATA version 9 for all of our statistical analyses and likelihood ratio tests to test for heterogeneity across categories. The study protocol was approved by the Nottingham Research Ethics Committee.
Results
We identified 9,682 people aged over 60 years who experienced a first fall and 52,100 matched controls (see Table 1 ). More than 88% of cases were matched to four or more controls; amongst the oldest cases, we secured fewer matched controls for each case. Nevertheless, each of our cases was successfully matched to at least one control of the exact same age, sex and general practice. The mean age of cases was 77.5 years and 76.4 years for controls. Thirty-two percent of cases and controls were male.
We recorded the results of our analyses of ever/never and previous/current prescribing in Table 2 . In our unadjusted analysis, we found significant odds ratios for all classes of medication, ranging from 1.10 (1.05-1.16) for beta blockers to 1.48 (1.37-1.61) for thiazides. After adjustment for prior diagnoses of CHD, co-morbidities and other antihypertensives, there were significant associations for For thiazides, the increased risk was significant for currently prescribed 1.28 (1.16-1.42) but not previously prescribed. In beta blockers, the protective effect was significant for currently prescribed 0.90 (0.85-0.96) but not previously prescribed. But for ACE inhibitors (the other class in which there was a significant association with first falls), the effect of current prescribing was weaker than for previously prescribed 1.07 (1.01-1.14).
In our adjusted analyses, we found no evidence of interaction with age, except for calcium channel blockers, in which there was a stronger positive association with first fall amongst those aged 60 to 75 years than in those aged over 75.
Our unadjusted and adjusted models of the risk of first fall after first prescription showed strong positive associations at 0 days for all classes of medication (except angiotensin-II receptor antagonists for which there were no cases in this subcategory) -see Table 3 . But amongst antihypertensives for elapsed times of 1-7, 8-14 and 15-21 days, only thiazides showed significant odds ratios. In days 1-7 following a first prescription, the adjusted odds ratio of first fall for thiazides was 5.41 (1.62-18.14), at 8-14 days was 5.02 (1.63-15.51) and at 15-21 days remained 4.28 (1.19-15.42 ).
When we validated our analysis by looking for the anticipated effects of antidepressants, we found a crude odds ratio of 1.78 (1.70-1.87) and an adjusted odds ratio of 1.67 (1.59-1.75). The adjusted odds ratio of first falls for current exposure to antidepressants was 2.23 (2.09-2.39) and significantly higher than that for previous exposure, which was 1.36 (1.29-1.45). At 1-7 days the adjusted odds ratio was 5.68 (2.74-11.80), at 8-14 days 1.68 (0.79-3.59) and at 15-21 days was 6.04 (3.12-11.70). In this large case-control study of older people using prospectively collected exposure data, we found that the risk of first fall for people ever prescribed thiazides was about 25% higher than for those never prescribed. This effect related to current prescribing and was stronger in the 3 weeks after the first prescription. We also found an increased risk for people ever prescribed ACE inhibitors but this increase related equally or more to those who had discontinued prescriptions as those currently prescribed. This does not suggest that ACE inhibitors cause falls but that the group given ACE inhibitors were at higher underlying risk of falls. For beta blockers, we found a small protective effect which related to current but not previous prescriptions. 
Strengths and weaknesses
The main strength of our study is the large number of cases, the completeness of the exposure data for prescribing and the fact that our data were collected prospectively which means that recall is not a source of bias. We differentiated medications according to standard classifications. Previous studies have demonstrated the validity of the data in THIN for pharmacoepidemiological research [8] [9] [10] . We validated the data and analysis used in this study by confirming the expected pattern of association between antidepressants and risk of falling.
The main potential weaknesses of our study are the validity of the recording of fall events, the possibility of differential non-compliance to medications, and incomplete control of confounding related to co-morbidity. Our previous study suggested that falls recorded in primary care are a subset of the falls self-reported in surveys [11] . This raises the possibility of differential ascertainment for patients receiving antihypertensive medication. Such a bias would increase the odds ratios. However, the fact that we found a mixture of positive, negative and non-significant effects between medication classes suggests that the effect of any ascertainment bias is negligible or small in some classes and probably small overall.
We cannot judge the extent, if any, of differential noncompliance to medication. But we note that non-compliance would result in underestimation of a true effect.
We have controlled for co-morbidity in two ways. Firstly, we checked for confounding by a number of conditions and medications associated with falls and, as a result, adjusted for diagnoses of CHD and for Charlson index which reduced the odds ratios in a way consistent with expectations. It should be noted that Charlson is designed as an index of 1 year mortality based on patients in a hospital setting and may not correlate fully with co-morbidity in a general population setting. Secondly, to explore the extent to which the effect was attributable to characteristics of the patients rather than the prescribing, we compared the risk for people currently and previously prescribed. Nevertheless, we acknowledge the possibility of residual confounding which could account for some or all of the positive effect observed for thiazides or an understatement of the protective effect of beta blockers.
Other studies
An association between antihypertensives and falls via orthostatic hypotension has been long suspected [1] , but the relationship with drug-related orthostatic hypotension is not clear [12, 13] . Leipzig et al.'s [2] review of medications and falls included observational studies of antihypertensives and other cardiovascular medications. The meta-analysis found weak associations with one or more falls for digoxin (OR 1.22), type 1A anti-arrhythmics (OR 1.59) and use of any diuretic (OR 1.08). Since 1999, studies have been inconsistent in their findings with regard to antihypertensives and risk of falls [14, 15] , with many providing only an aggregated classification of antihypertensives [16] . Setting out to test the hypothesis that associations between medications and falls are confounded by medical conditions, Lee et al. [17] found no association with falls for most cardiovascular and noncardiovascular medication groups (including psychotropics), except for nitrates.
What does it mean clinically?
The association between first recorded fall and prescribing of thiazides is consistent with the hypothesis that this class of antihypertensive medication is an independent risk factor for falls and that the risk is greatest in the first 3 weeks after the start of prescribing. The mechanism by which this occurs is not clear. However, the literature indicates an initial hypotensive response to thiazide diuretics in the first few weeks of treatment, mediated by a reduction in plasma volume and cardiac output, and that these return to near baseline levels over several weeks with the longer term reduction in blood pressure driven by different underlying mechanisms [18, 19] . This may explain the change in risk with time since initiation of treatment. Other possible explanations for the decrease in risk in consecutive weeks include the development of biological tolerance or coping mechanisms, or a degree of survival bias in which patients reporting problems are taken off the medication in the first 3 weeks, leaving a group of cases who are less susceptible to further falls.
The size of the observed association with thiazides is small; despite this, the potential public health impact of such an effect could be significant, given the high incidence of prescribing. The Hypertension in the Very Elderly Trial demonstrated the benefit of hypertensive treatment, based on a diuretic with or without an additional ACE inhibitor, in reducing the risk of death from stroke, death from any cause and heart failure in the very elderly. Our study reminds clinicians initiating prescribing of thiazides in older people to be alert to the possibility of an increased risk of falls.
The reduced risk with prescribing of beta blockers could be causal, but it is not clear what this mechanism could be. In part, it may be explained by a possible protective effect for vasovagal syncope, in which the beta blocker attenuates the raised levels of catecholamine preceding syncope [20] . The observed effect may also be due to residual confounding resulting from, for example, less underlying frailty in the group prescribed beta blockers.
Conclusion
Our study provides evidence that thiazides are associated with an increased risk of first falls and that this persists for at least the first 3 weeks of exposure, which suggests that this class of medication may not be as safe as previously thought. There was no increase in falls risk for other classes of antihypertensive medication.
Key points
• Antihypertensive medications have long been implicated as a potential cause of falls in older people via orthostatic hypotension but data about their effect on falls is inconsistent.
• This study shows that in routine primary care practice, thiazides are associated with an increased risk of first falls, which suggests that this class of medication may not be as safe as previously thought.
• There was no increase in falls risk for current prescribing of other classes of antihypertensive.
